788 610

Cited 0 times in

Mitochondrial Permeability Transition Pore와 허혈-재관류 손상으로부터의 심근보호작용

DC Field Value Language
dc.contributor.author심연희-
dc.contributor.author이종화-
dc.date.accessioned2015-04-24T16:57:56Z-
dc.date.available2015-04-24T16:57:56Z-
dc.date.issued2009-
dc.identifier.issn1975-8456-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/104504-
dc.description.abstractOpening of mitochondrial permeability transition pore (mPTP) was found to have a critical role in cell death from ischemia/reperfusion (I/R) injury experimentally in the late 1980’s. Thereafter, tremendous efforts have been made to define the molecular composition of mPTP and underlying mechanisms of its opening. mPTP opening, so far, has been demonstrated with the conformational changes of the mitochondrial protein components including cyclophilin-D, adenine nucleotide translocase, and voltage-dependent anion channel, which were induced by the modification of the levels of Ca2+, phosphate, mitochondrial membrane potential, intracellular pH and adenine nucleotide. At present, genetic modulation of the expression of protein components are being used in the investigation of its properties, presenting novel mechanisms of mPTP opening, including phosphate carrier. For therapeutic intervention, cyclosporin A and its analogues were first to be demonstrated to inhibit the opening of mPTP, affecting cyclophilin-D. There are numerous pharmacological substances that have direct or indirect effects on mPTP opening, including bongkrekic acid, reactive oxygen species scavengers, calcium channel blockers, and Na+/H+ exchanger-1 inhibitors, but only cyclosporin A was clinically tried to limit the myocardial infarction. Conditioning interventions, ischemic or anesthetic, have also been shown to be effective in limiting the detrimental effects of I/R injury. These interventions are commonly related to specific receptors on cell membrane and then signal transduction pathway consisting of many protein kinases, which eventually lead to mitochondria. And being presented are experimental evidences that inhibition of mPTP opening is a primary mechanism of these conditioning interventions. In conclusion, mPTP opening is now presented as primary mechanism and therapeutic target of I/R injury, but precise mechanism and standardized treatment method are needed to be clarified-
dc.description.statementOfResponsibilityopen-
dc.format.extent1007~1019-
dc.languageJOURNAL OF THE KOREAN MEDICAL ASSOCIATION-
dc.publisherJOURNAL OF THE KOREAN MEDICAL ASSOCIATION-
dc.relation.isPartOfJOURNAL OF THE KOREAN MEDICAL ASSOCIATION-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleMitochondrial Permeability Transition Pore와 허혈-재관류 손상으로부터의 심근보호작용-
dc.title.alternativeMitochondrial Permeability Transition Pore and Cardioprotection Against Ischemia-reperfusion Injury-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Anesthesiology (마취통증의학)-
dc.contributor.googleauthor이종화-
dc.contributor.googleauthor심연희-
dc.identifier.doi10.5124/jkma.2009.52.10.1007-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02196-
dc.contributor.localIdA03154-
dc.relation.journalcodeJ01833-
dc.identifier.eissn2093-5951-
dc.subject.keywordMitochondrial permeability transition pore-
dc.subject.keywordCardioprotection-
dc.subject.keywordIschemia/reperfusion injury-
dc.subject.keywordMyocardium-
dc.contributor.alternativeNameShim, Yon Hee-
dc.contributor.alternativeNameLee, Jong Wha-
dc.contributor.affiliatedAuthorShim, Yon Hee-
dc.contributor.affiliatedAuthorLee, Jong Wha-
dc.citation.volume52-
dc.citation.number10-
dc.citation.startPage1007-
dc.citation.endPage1019-
dc.identifier.bibliographicCitationJOURNAL OF THE KOREAN MEDICAL ASSOCIATION, Vol.52(10) : 1007-1019, 2009-
dc.identifier.rimsid54170-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Anesthesiology and Pain Medicine (마취통증의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.